医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期

交银国际2025-12-18

行情回顾：本周（2025/12/9-12/16）恒指跌0.8%，恒生医疗保健指数跌4.3%，行业指数中排第 12 位，跑输大市。子行业：医院（-1.0%）、中药（-1.4%）、CXO（-1.5%）、流通（-2.0%）、生物药（-3.7%）、器械（-3.9%）、互联网医药（-4.5%）、处方药（-5.3%）。机构持仓回顾：10 月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592490556?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-18 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2592490556","market":"hk","top_or_hot":-1,"title":"医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期","media":"交银国际","content":"<div>\n<p>行情回顾：本周（2025/12/9-12/16）恒指跌0.8%，恒生医疗保健指数跌4.3%，行业指数中排第 12 位，跑输大市。子行业：医院（-1.0%）、中药（-1.4%）、CXO（-1.5%）、流通（-2.0%）、生物药（-3.7%）、器械（-3.9%）、互联网医药（-4.5%）、处方药（-5.3%）。机构持仓回顾：10 月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药行业周报：年末国产创新药出海交易密集落地 2026年向上趋势中价值回归可期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-18 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b><strong>交银国际</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>行情回顾：本周（2025/12/9-12/16）恒指跌0.8%，恒生医疗保健指数跌4.3%，行业指数中排第 12 位，跑输大市。子行业：医院（-1.0%）、中药（-1.4%）、CXO（-1.5%）、流通（-2.0%）、生物药（-3.7%）、器械（-3.9%）、互联网医药（-4.5%）、处方药（-5.3%）。机构持仓回顾：10 月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0359201885.HKD","symbol_name":"BGF CHINA \"A2\" (HKD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","article_id":"2592490556","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218192135a45b4ef9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592490556","pubTimestamp":1765987200,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"本周内资主要加仓龙头创新药企，包括恒瑞医药、荣昌生物和映恩生物；亦布局潜在受益于下游复苏的龙头CXO 企业，增持昭衍新药、晶泰控股和药明合联。投资启示：本周多项超10 亿美元的BD 交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，我们继续看好新BD 交易集中落地机会。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK1191":"制药","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","01276":"恒瑞医药","06978":"永泰生物-B","BK1161":"生物科技","BK1574":"生物医药B类股","02192":"医脉通","LU0359201612.USD":"贝莱德中国基金A2","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H"},"translate_title":"Pharmaceutical Industry Weekly Report: Domestic innovative drugs will be intensively transacted overseas at the end of the year, and the value return is expected amid the upward trend in 2026","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":0.9,"06978":1.5,"02192":0.9},"content_text":"行情回顾：本周（2025/12/9-12/16）恒指跌0.8%，恒生医疗保健指数跌4.3%，行业指数中排第 12 位，跑输大市。子行业：医院（-1.0%）、中药（-1.4%）、CXO（-1.5%）、流通（-2.0%）、生物药（-3.7%）、器械（-3.9%）、互联网医药（-4.5%）、处方药（-5.3%）。机构持仓回顾：10 月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。本周内资主要加仓龙头创新药企，包括恒瑞医药、荣昌生物和映恩生物；亦布局潜在受益于下游复苏的龙头CXO 企业，增持昭衍新药、晶泰控股和药明合联。外资布局方向则较为分散，但整体围绕高性价比子板块和标的，加仓方向包括互联网医疗（医脉通、平安好医生和阿里健康）和中小市值创新药械（微创脑科学、加科思和和铂医药）。投资启示：本周多项超10 亿美元的BD 交易相继落地，合作伙伴既有MNC也有中小型生物科技公司。临近年末，我们继续看好新BD 交易集中落地机会。展望2026 年，我们认为板块稳中向好态势延续，但影响市场表现的核心因素（政策、基本面、海外投融资环境、资金面等）或呈分化态势，后续选股逻辑或将重回基本面和估值，即关注存在基本面预期差、当前仍被低估的个股。推荐关注以下细分方向：1）创新药：三生制药、德琪医药、百济神州等催化剂丰富、估值仍未反映核心大单品价值；先声药业、传奇生物被明显低估、长期成长逻辑清晰；2）CXO：受益于下游高景气度和融资边际回暖的细分赛道龙头，如药明合联；3）监管不确定性逐步释放，有反转机会的医院、器械和诊断等子板块。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592490556","isCrawlerRequest":true}